These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 24322398

  • 21. Influence of diuretics, calcium antagonists, and alpha-blockers on insulin sensitivity and glucose tolerance in hypertensive patients.
    Ramsay LE, Yeo WW, Jackson PR.
    J Cardiovasc Pharmacol; 1992; 20 Suppl 11():S49-53; discussion S53-4. PubMed ID: 1284144
    [Abstract] [Full Text] [Related]

  • 22. Randomized study to compare valsartan +/- HCTZ versus amlodipine +/- HCTZ strategies to maximize blood pressure control.
    Zappe D, Papst CC, Ferber P, PROMPT Investigators.
    Vasc Health Risk Manag; 2009; 5():883-92. PubMed ID: 19898644
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Effect of renin-angiotensin system blockade on soluble Klotho in patients with type 2 diabetes, systolic hypertension, and albuminuria.
    Karalliedde J, Maltese G, Hill B, Viberti G, Gnudi L.
    Clin J Am Soc Nephrol; 2013 Nov; 8(11):1899-905. PubMed ID: 23929932
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. New-onset diabetes and antihypertensive drugs.
    Mancia G, Grassi G, Zanchetti A.
    J Hypertens; 2006 Jan; 24(1):3-10. PubMed ID: 16331092
    [Abstract] [Full Text] [Related]

  • 28. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect.
    Viberti G, Wheeldon NM, MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators.
    Circulation; 2002 Aug 06; 106(6):672-8. PubMed ID: 12163426
    [Abstract] [Full Text] [Related]

  • 29. Beta-blockers and cardiovascular outcomes in dialysis patients: a cohort study in Ontario, Canada.
    Kitchlu A, Clemens K, Gomes T, Hackam DG, Juurlink DN, Mamdani M, Manno M, Oliver MJ, Quinn RR, Suri RS, Wald R, Yan AT, Garg AX.
    Nephrol Dial Transplant; 2012 Apr 06; 27(4):1591-8. PubMed ID: 21873621
    [Abstract] [Full Text] [Related]

  • 30. A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study.
    Malacco E, Varì N, Capuano V, Spagnuolo V, Borgnino C, Palatini P, Val-Syst study.
    Clin Ther; 2003 Nov 06; 25(11):2765-80. PubMed ID: 14693303
    [Abstract] [Full Text] [Related]

  • 31. Prospective relationships between body weight and physical activity: an observational analysis from the NAVIGATOR study.
    Preiss D, Thomas LE, Wojdyla DM, Haffner SM, Gill JM, Yates T, Davies MJ, Holman RR, McMurray JJ, Califf RM, Kraus WE, NAVIGATOR Investigators.
    BMJ Open; 2015 Aug 14; 5(8):e007901. PubMed ID: 26275900
    [Abstract] [Full Text] [Related]

  • 32. Risk of incident diabetes among patients treated with statins: population based study.
    Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM.
    BMJ; 2013 May 23; 346():f2610. PubMed ID: 23704171
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. The risk of myocardial infarction associated with antihypertensive drug therapies.
    Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, Weiss NS, Rosendaal FR, Lemaitre RN, Smith NL, Wahl PW.
    JAMA; 2013 May 23; 274(8):620-5. PubMed ID: 7637142
    [Abstract] [Full Text] [Related]

  • 35. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design.
    Mann J, Julius S.
    Blood Press; 1998 May 23; 7(3):176-83. PubMed ID: 9758088
    [Abstract] [Full Text] [Related]

  • 36. Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: the VALUE trial.
    Kjeldsen SE, McInnes GT, Mancia G, Hua TA, Julius S, Weber MA, Coca A, Girerd X, Jamerson K, Larochelle P, Macdonald T, Schmieder RE, Anthony Schork M, Viskoper R, Widimsky J, Zanchetti A.
    Blood Press; 2008 May 23; 17(3):170-7. PubMed ID: 18608200
    [Abstract] [Full Text] [Related]

  • 37. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial).
    Califf RM, Lokhnygina Y, Velazquez EJ, McMurray JJ, Leimberger JD, Lewis EF, Diaz R, Murin J, Pfeffer MA.
    Am J Cardiol; 2009 Jul 15; 104(2):151-7. PubMed ID: 19576338
    [Abstract] [Full Text] [Related]

  • 38. [Effects of antihypertensive drugs on glucose metabolism and cardiovascular events].
    Landmark K, Reikvam A.
    Tidsskr Nor Laegeforen; 2009 Sep 10; 129(17):1740-4. PubMed ID: 19756054
    [Abstract] [Full Text] [Related]

  • 39. Diabetes mellitus in treated hypertension: incidence, predictive factors and the impact of non-selective beta-blockers and thiazide diuretics during 15 years treatment of middle-aged hypertensive men in the Primary Prevention Trial Göteborg, Sweden.
    Samuelsson O, Hedner T, Berglund G, Persson B, Andersson OK, Wilhelmsen L.
    J Hum Hypertens; 1994 Apr 10; 8(4):257-63. PubMed ID: 7912734
    [Abstract] [Full Text] [Related]

  • 40. The relationship between antihypertensive combination therapies comprising diuretics and/or beta-blockers and the risk of new-onset diabetes: a retrospective longitudinal cohort study.
    Liou YS, Ma T, Tien L, Lin CM, Jong GP.
    Hypertens Res; 2009 Jun 10; 32(6):496-9. PubMed ID: 19390541
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.